Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

2020’s Emerging Leaders Prize awards £200,000 to outstanding scientists from the University of Oxford, University College London and King’s College London, who are all working in the field of pain research.

Annina Schmid in the lab © Nicholas Irving

Patients with nerve injuries often develop persistent nerve-related pain. A staggering 10 per cent of the general population experience such nerve-related symptoms, yet we do not understand why some patients recover whereas others continue to have symptoms for many years.

I am honoured to be the first allied health professional to receive this prestigious prize. It will not only allow me to answer an innovative and potentially game-changing research question, but it will also put physiotherapy pain research in the international spotlight.
- Annina Schmid

Annina Schmid, a Specialist Physiotherapist and an Associate Professor, won second place, with a prize of £80,000. Her research examines why some patients with nerve injuries recover whereas others develop persistent pain. To achieve this, she uses an exciting mix of methodologies, ranging from advanced neuroimaging to sensory profiling and analyses of human bio-samples. 

The prize funding will allow Dr Schmid to build on her recent discoveries in patients with whiplash injury. She will examine whether injury to small nerve fibres in the skin explains why up to 50 per cent of people develop persistent pain after whiplash injury, and will also explore whether there are differences in skin gene expression between patients who have and have not recovered.

Dr Schmid said: 'Funding from the Emerging Leaders Prize will allow me to investigate whether an injury to small nerve fibres explains why some patients develop persistent pain after whiplash injury. Importantly, I will examine whether low-cost bedside sensory tests that I have developed can identify such small fibre damage. This will enable early targeted intervention to prevent pain persistence.'

Read more on the Medical Research Foundation website

Similar stories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Clinical Neurology Research

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Low-cost ventilator wins at E&T Innovation Awards

Anaesthetics Award Coronavirus

The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.